Page 1

Q2 Alligator Bioscience AB ( publ ) Interim report January - June 2021 Positive Phase I data for ATOR - 1017 ALLIGATOR ; bioscience Significant events April - June Pipeline ⚫ An article prepared by scientists at Alligator , on CD40 agonistic antibodies was published in Expert Opinion on Biological Therapy . ⚫ATOR - 1017 is the first monoclonal 4-1 BB agonist antibody to show good safety and signs of efficacy . This interim data from the ongoing Phase I clinical study was presented at the 2021 ASCO Annual Meeting . Preclinical data on the anti - CD40 antibody mitazalimab were published in the scientific journal Cancer Immunology , Immunotherapy . Alligator and the Swedish biopharma company BioArctic AB enter- ed into a joint research agreement in the neurodegenerative field . Alligator and the US biopharmaceutical company MacroGenics en- tered into a joint research collaboration to develop Neo - X - Prime ™ . Alligator and Scandion Oncology presented promising preclini- cal data from collaboration exploring the anti - tumor efficacy of mitazalimab in combination with chemotherapy and SCO - 101 . Company ⚫ The Board member Carl Borrebaeck , who had declined re - election ahead of the Annual General Meeting on June 1 , 2021 , resigned from the Board of Directors at his own request . Søren Bregenholt took over as CEO on 1 June . . At the AGM Anders Ekblom and Graham Dixon were re - elected as board members , and Hans - Peter Ostler , Eva Sjökvist Saers and Veronica Wallin were elected as new board members Anders Ekblom was elected as new Chairman of the board , and Hans - Peter Ostler was elected as new Vice Chairman of the board . " As new CEO of Alligator Bioscience , after just around a month , let me say that my high expectations on the company have been surpassed already . During this short time , I have been ascertained that Alligator has a strong pipeline that builds on a powerful technology platform . " Søren Bregenholt CEO Alligator Bioscience AB ( publ ) Financial summary April - June 2021 ⚫ Net sales , SEK 3.8 million ( 4.4 ) Operating result , SEK - 34.5 million ( -34.7 ) ⚫ Result for the period , SEK - 35 million ( -35.1 ) • Earnings per share before and after dilution , SEK -0.41 ( -0.49 ) ⚫ Cash flow for the period , SEK -34.0 million ( -33.2 ) ⚫ Cash and cash equivalents , incl . interest - bearing securities , SEK 109.7 million ( 169.8 ) January - June 2021 ⚫ Net sales , SEK 4.4 million ( 4.4 ) • Operating result , SEK -67.0 million ( -79.6 ) ⚫ Result for the period , SEK -67.7 million ( -77.9 ) • Earnings per share before and after dilution , SEK -0.79 ( -1.09 ) ⚫ Cash flow for the period , SEK 6.4 million ( 75.4 ) DISCOVERY Neo - X - Prime ™ The information was submitted for publication at 8:00 a.m. CET on July 13 , 2021. For contact details , see page 13 . PRECLINICAL 1 Alligator Bioscience AB | Interim report January - June 2021 CLINICAL PHASE I ALG.APV - 527 CLINICAL PHASE II ATOR - 1017 Mitazalimab AC101 Introduction